載入...
Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
AIMS: To illustrate the use of pharmacokinetic–pharmacodynamic (PK–PD) models to select rational starting doses in clinical trials within the minimum anticipated biological effect level (MABEL) principle using literature data and through simulations. METHODS: The new European Medicines Agency guidan...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Blackwell Science Inc
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2670372/ https://ncbi.nlm.nih.gov/pubmed/19076987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2008.03297.x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|